Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 612 participants.
Also called NCT02480764
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 612 participants
- Sponsor
- Registry
-
NCT02480764 -
U1111-1159-5579
-
- Other papers using this trial's data
- A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02480764. Randomized; quadruple masking; primary purpose treatment. Start 2015-08-27 (actual); primary completion 2017-09-22 (actual). Results posted on 2019-02-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Azilsartan medoxomil
- Intervention (Drug)
- Valsartan
- Intervention (Drug)
- Azilsartan medoxomil Placebo
- Intervention (Drug)
- Valsartan Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02480764- Content hash
4ad710f6411d45f9896a8c44572ff232a595aa4d3ab7ae412131caa388e76a25